Shilpa Medicare Ltd
NSE:SHILPAMED
Shilpa Medicare Ltd
Pre-Tax Income
Shilpa Medicare Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shilpa Medicare Ltd
NSE:SHILPAMED
|
Pre-Tax Income
₹1.3B
|
CAGR 3-Years
28%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
3%
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Pre-Tax Income
₹72.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Pre-Tax Income
₹65.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
23%
|
CAGR 10-Years
15%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Pre-Tax Income
₹133.1B
|
CAGR 3-Years
21%
|
CAGR 5-Years
21%
|
CAGR 10-Years
6%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Pre-Tax Income
₹26.4B
|
CAGR 3-Years
16%
|
CAGR 5-Years
29%
|
CAGR 10-Years
9%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Pre-Tax Income
₹24B
|
CAGR 3-Years
12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shilpa Medicare Ltd
Glance View
Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.
See Also
What is Shilpa Medicare Ltd's Pre-Tax Income?
Pre-Tax Income
1.3B
INR
Based on the financial report for Dec 31, 2024, Shilpa Medicare Ltd's Pre-Tax Income amounts to 1.3B INR.
What is Shilpa Medicare Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
3%
Over the last year, the Pre-Tax Income growth was 502%. The average annual Pre-Tax Income growth rates for Shilpa Medicare Ltd have been 28% over the past three years , -5% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet